A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families.

@article{Peelen1997AHP,
  title={A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families.},
  author={T. A. Peelen and Marleen van Vliet and Anne Petrij-Bosch and R. H. P. Mieremet and Czaba Szab{\'o} and Ans M. W. van den Ouweland and F. Hogervorst and Richard M. Brohet and Marjolijn J. L. Ligtenberg and Erik Teugels and Rob B van der Luijt and Annemarie H. van der Hout and Jan JP Gille and Gerald Pals and Inge Jedema and Renske Olmer and Inge van Leeuwen and B. B. Newman and M Plandsoen and M N van der Est and Gijs R. van den Brink and Sandra Hageman and Petronella J.W. Arts and M E C Mari{\"e}lle Bakker and Peter Devilee},
  journal={American journal of human genetics},
  year={1997},
  volume={60 5},
  pages={1041-9}
}
We have identified 79 mutations in BRCA1 in a set of 643 Dutch and 23 Belgian hereditary breast and ovarian cancer families collected either for research or for clinical diagnostic purposes. Twenty-eight distinct mutations have been observed, 18 of them not previously reported and 12 of them occurring more than once. Most conspicuously, a 2804delAA mutation has been found 19 times and has never been reported outside the Netherlands. A common haplotype spanning > or = 375 kb could be identified… CONTINUE READING